Get started
Author

Kishor N. Vora

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315
PDF
The Changing Landscape for Stroke Prevention in AF
2017 · Menno V. Huisman, Kenneth J. Rothman, et al. · Journal of the American College of Cardiology · 280
PDF
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
2019 · Deepak L Bhatt, Philippe Gabriel Steg, et al. · The Lancet · 209
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
2016 · Sean D. Pokorney, Jonathan P. Piccini, et al. · Journal of the American Heart Association · 201
PDF
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148
PDF
Excimer laser angioplasty in acute myocardial infarction (the CARMEL multicenter trial)
2004 · On Topaz, Douglas Ebersole, et al. · The American Journal of Cardiology · 127
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118
PDF
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
2018 · Erin A Bohula, Benjamin M Scirica, et al. · The Lancet · 93
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
2022 · Jean-François Rossignol, C. Bardin Matthew, et al. · EClinicalMedicine · 53
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
2021 · Subodh Verma, Subodh Verma, et al. · The Lancet Diabetes & Endocrinology · 47
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
2023 · Giulio Francesco Romiti, Bernadette Corica, et al. · EClinicalMedicine · 45
PDF
Safety and Performance of Targeted Renal Therapy: The Be-RITe! Registry
2009 · Giora Weisz, Steven J. Filby, et al. · Journal of Endovascular Therapy · 44
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40
PDF
Excimer laser revascularization of saphenous vein grafts in acute myocardial infarction.
2004 · Douglas Ebersole, Johannes B Dahm, et al. · PubMed · 37
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
2022 · Gregory Y. H. Lip, Agnieszka Kotalczyk, et al. · Clinical Research in Cardiology · 33
PDF
Prevention of distal embolization and no-reflow in patients with acute myocardial infarction and total occlusion in the infarct-related vessel: A subgroup analysis of the cohort of acute revascularization in myocardial infarction with excimer laser?CARMEL multicenter study
2004 · Johannes B. Dahm, Douglas Ebersole, et al. · Catheterization and Cardiovascular Interventions · 30
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26
PDF
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25
PDF
Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q)
2007 · CARMEL Excimer Laser Interventional Study Group, On Topaz, et al. · Lasers in Medical Science · 19
Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study
2021 · Gary F. Mitchell, Scott D. Solomon, et al. · Circulation Heart Failure · 13
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
2020 · Benjamin A. Steinberg, DaJuanicia N. Holmes, et al. · Circulation Arrhythmia and Electrophysiology · 12
Systemic Hypothermia to Prevent Radiocontrast Nephropathy (from the COOL-RCN Randomized Trial)
2011 · Gregg W. Stone, Kishor Vora, et al. · The American Journal of Cardiology · 9
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
2023 · Wern Yew Ding, Ameenathul Mazaya Fawzy, et al. · Journal of Thrombosis and Thrombolysis · 7
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
2020 · George Ntaios, Menno V. Huisman, et al. · Hellenic Journal of Cardiology · 3
PDF
Results from a pilot study to determine the feasibility in transitioning outpatient CHF patients from intermittent intravenous inotrope therapy to nesiritide
2003 · Joshua P. Squiers, Kishor N. Vora · Journal of Cardiac Failure · 2
Works count: 41
Citation count: 2,466
H-index: 22
I10-index: 25
Year
Topic
Type